Citation Impact
Citing Papers
Structures of a Na + -coupled, substrate-bound MATE multidrug transporter
2013
Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis
2006
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
2010
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
2009
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Advances in targeted degradation of endogenous proteins
2019
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
2012
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
De novo design of immunoglobulin-like domains
2022 StandoutNobel
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
2008
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
2020 StandoutNobel
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Pyrin, product of the MEFV locus, interacts with the proapoptotic protein, Siva
2008
Improvements to the Kunkel mutagenesis protocol for constructing primary and secondary phage-display libraries
2012
Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice
2011 StandoutNobel
Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer
2013
Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs
2014
Enhancement of T‐cell‐mediated anti‐tumour immunity via the ectopically expressed glucocorticoid‐induced tumour necrosis factor receptor‐related receptor ligand (GITRL) on tumours
2008 StandoutNobel
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
2008
Continuous evolution of Bacillus thuringiensis toxins overcomes insect resistance
2016 Nature
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
2017 StandoutNature
Modulation of Cell Cycle Components by Epigenetic and Genetic Events
2005
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
2006
Continuous directed evolution of proteins with improved soluble expression
2018
Antibody therapy of cancer
2012 Standout
RB and cell cycle progression
2006 Standout
Inflammation and Colon Cancer
2010 Standout
p27 Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy
2006
Targeting apoptosis in cancer therapy
2020 Standout
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
2007
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mechanisms of mitophagy
2010 Standout
Search-and-replace genome editing without double-strand breaks or donor DNA
2019 StandoutNature
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
2005
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Phylogenomics of Life-Or-Death Switches in Multicellular Animals: Bcl-2, BH3-Only, and BNip Families of Apoptotic Regulators
2005
End-to-end design of wearable sensors
2022 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
The BCL-2 protein family: opposing activities that mediate cell death
2007 Standout
Cervical cancer
2019 Standout
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
2006
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Multidrug efflux pumps: structure, function and regulation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
2007
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
2009
Monobodies and other synthetic binding proteins for expanding protein science
2017
A first synthesis of 18F‐radiolabeled lapatinib: a potential tracer for positron emission tomographic imaging of ErbB1/ErbB2 tyrosine kinase activity
2011
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
2006
GITR-GITRL System, A Novel Player in Shock and Inflammation
2007
Lapatinib: Current Status and Future Directions in Breast Cancer
2006
Drug Resistance in Cancer: An Overview
2014 Standout
Design of ordered two-dimensional arrays mediated by noncovalent protein-protein interfaces
2015 StandoutScienceNobel
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
2015 Standout
Works of John Barkinge being referenced
Expression of Siva-1 Protein or Its Putative Amphipathic Helical Region Enhances Cisplatin-Induced Apoptosis in Breast Cancer Cells: Effect of Elevated Levels of BCL-2
2005
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
2010
Siva-1 negatively regulates NF-κB activity: effect on T-cell receptor-mediated activation-induced cell death (AICD)
2006
The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis
2004
Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective
2008